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G ene therapy techniques offer the opportunity of delivering exogenous genes to human cells in vivo.
Many efforts (in this field ) have been focused on the development of new anticancer strategies. A variety of gene therapy approaches have the common goal of expressing a gene that will specifically kill cancer cells. 1 The lethal gene to be used can encode a pro -drug ± activating enzyme, an immunomodulatory agent, or a pro -apoptotic molecule, among others. 2 In all these cases, a method to selectively express the gene in cancer cells is desirable to increase antitumor efficiency and to avoid side effects due to the death of normal cells. This can be achieved if a promoter that is preferentially active in the tumor is used to control the expression of the therapeutic gene. Therefore, the identification of such promoters is a major topic in cancer research. 3 Some cancer cells express proteins that are not produced in most of the normal tissues. This is the case of thefetoprotein ( -FP ) in hepatocellular carcinoma, or the carcinoembryonic antigen (CEA ) in colon cancer. The promoters of these proteins have been used to direct the expression of pro -drug ± activating enzymes like thymidine kinase or cytosine deaminase. 4 ± 6 Interestingly, when the -FP promoter was used to control the expression of the E1A gene of adenovirus, a conditionally replicative virus that preferentially replicated in hepatocarcinoma cells was obtained. 7 In other circumstances like prostate cancer, tissue -specific promoters ( prostate -specific antigen promoter or glandular kallikrein 2 promoter ) can be used because the prostate is an accessory gland and the destruction of the normal tissue is well tolerated. 8 Other similar approaches include the use of the tyrosinase promoter to target melanoma, 9 or the osteocalcin promoter for osteocarcinoma. 10 For many other cancers, no specific promoter has been identified so far. This is the case of breast cancer, the most frequent malignancy affecting women besides skin cancers. Still, preferential expression of therapeutic genes in breast cancer has been described using tissue -specific promoters such as the human -lactalbumin or the ovinelactoglobulin promoters. 11, 12 Recently, the E1 a gene of adenovirus was placed under the transcriptional control of the MUC -1 promoter. The MUC -1 protein is overexpressed in a proportion of breast cancers, as well as other cancers and normal tissues. 13 Using this strategy, Kurihara et al 14 reported the construction of an adenovirus that specifically replicated in MUC -1 ±overexpressing breast cancer cells.
In a similar way, we have already described a novel, conditionally replicative adenovirus for the treatment of breast cancer. 15 In this case, we placed both the E1 a and E4 transcription units of adenovirus under the control of a promoter that contained estrogen response elements (EREs). These sequences are recognized by the estrogen receptors ( ERs ), which are intracellular receptors that act as transcription factors to activate the expression of genes in the presence of estrogens. 16 Up to 70% of breast cancers retains the expression of ERs, 17 and only if these receptors are present in the cells will a promoter containing EREs be activated by estrogens. In addition, this system allows the modulation of the response by antiestrogenic drugs such as tamoxifen.
All the examples mentioned above point out the importance of studying the individual characteristics of each type of cancer to find opportunities for transcriptional targeting. In addition, a common characteristic of many solid tumors is the existence of a hypoxic microenvironment inside the lesion. 18, 19 In these circumstances, cells express a transcription factor called hypoxia-inducible factor ( HIF ) that activates the expression of several genes in the context of a global response to hypoxia. 20, 21 Indeed, there is evidence indicating that HIF is necessary for solid tumor formation. 22 HIF binds to a consensus sequence called hypoxia -responsive element ( HRE ) in the promoter of these genes. The use of this HRE has been reported to direct the expression of therapeutic genes to solid tumors. 23, 24 More recently, the HRE was used in combination with cytokineinducible enhancers to direct the expression of genes to endothelial cells. 25 In the present work, our purpose was to develop an artificial hybrid promoter to direct the expression of genes to breast tumors. We explored the possibility of combining both EREs and HREs in the same promoter. The HRE was used as an enhancer to obtain maximum transcriptional activation in ER + cells growing under hypoxic conditions, as well as retaining some degree of activity even if the cells lose the expression of ERs. Apart from transcriptional assays, we investigated the feasibility of using this new promoter for the treatment of cancer.
Programmed cell death, or apoptosis, is an important cellular process that maintains the homeostasis of tissues in a multicellular organism. 26 The elements that control this critical event are still being investigated. The balance between pro -apoptotic and antiapoptotic proteins is tightly regulated to achieve a physiological response. 27 Alterations in this equilibrium can determine the appearance and progression of tumors, as well as the response to anticancer treatments. 28 Several pro -apoptotic genes have been used in gene therapy approaches to fight cancer. 29 ± 31 In this work, we describe the construction and characterization of a replication-deficient adenovirus vector that expresses harakiri, a potent pro -apoptotic gene, 32 under the control of the new ER and hypoxia-specific promoter. We show evidence that this promoter can be used to direct the expression of a lethal gene and achieve controlled killing of breast cancer cells.
MATERIALS AND METHODS

Cell culture
We used five different human breast cancer cell lines. MCF7 ( ATTC HTB 22), T-47D (ATTC HTB 133 ), and BT-474 ( ATTC HTB 20) are ER +, whereas MDA -MB -231 (ATTC HTB 26) and SK -BR -3 ( ATTC HTB 30 ) are ER À . These cells were maintained in RPMI medium ( BioWhittaker, Walkersville, MN ) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT ) and 10 g /mL insulin ( Gibco BRL, Grand Island, NY ). NB2F are primary human fibroblasts isolated from normal breast. They were maintained in Ham's F -12 (BioWhittaker ) supplemented with 5 g /mL insulin, 1 g /mL hydrocortisone, 10 ng/ mL epidermal growth factor (EGF ), and 100 ng/ mL cholera toxin. When the experiment required depletion of estrogens, improved MEM without phenol red ( Gibco BRL ) was used, supplemented with 2.5% charcoal -dextran stripped serum ( Hyclone ). Estradiol (17 -Estradiol ) and 4-OH -Tamoxifen were purchased from Sigma (Saint Louis, MO ). All culture media were supplemented with 100 U /mL penicillin, 100 U /mL streptomycin, and 0.25 g/mL fungizone ( BioWhittaker ). Hypoxia was induced by placing the cells in a sealed chamber that had been gassed with a mixture of 1% O 2 , 6% CO 2 balanced with N 2 .
Characterization of the ERE / HRE promoter and construction of plasmids A cassette containing three copies of the HRE consensus element of the mouse phosphoglycerate kinase -1 (PGK -1 ) 5
H enhancer ( TGTCACGTCCTGCACGAC ) 23 flanked by ClaI sites was subcloned in the ClaI site of the plasmid pERE2pS2CAT. 33 This plasmid contains a portion of the pS2 promoter ( À 90/ + 10 bp), plus two of its EREs. The artificial promoter was liberated by digestion with EcoRI and BsrI, and subcloned into the SmaI site of the luciferase reporter plasmid pGL2Basic (Promega, Madison, WI ). To verify the response to estrogens and hypoxia, the new construct ( pBERE /HRE ) was transfected into T-47D, MCF7, BT-474, and MDA -MB-231 cells using the Fugene 6 reagent, as described by the manufacturer (Roche, Indianapolis, IN ). The cells (typically 7.5Â10 4 /well in a 12 -well plate ) were seeded in estrogen -free medium and transfected 24 hours later using 0.3 g /well of pBERE / HRE and 0.1 g/well of the plasmid pRLTK ( Promega ) to quantify the efficiency of transfection. To confirm the specificity of transcriptional activation, a reporter with a constitutive SV40 promoter (pGL2 -Control ) was transfected in MCF7 cells in the same conditions as pBERE / HRE. The luciferase activity obtained after transfection with the promoterless plasmid pGL2 -Basic was considered as basal activity. Six hours later, the transfection medium was removed and new medium was added containing the indicated treatments. After 16 ± 18 hours, cells were lysed and analyzed for luciferase activity using the Dual Luciferase Reporter Assay System (Promega ), as indicated by the manufacturer. The specific luciferase activity measured in a luminometer is presented as ( firefly / renilla )Â10 3 luciferase units. The plasmid pBEHhrk contains the harakiri gene under the control of the ERE /HRE promoter. It was obtained by blunt -end ligation of the HindIII ± XbaI fragment of pCDNA -hrk ( containing the harakiri gene ) 32 into the BglII ±EcoNI sites of pBERE/ HRE.
X -Gal staining of cells in culture
To score the proportion of apoptotic cells after transfection with the pBEHhrk plasmid, MCF7 cells were co-transfected with 0.3 g pBEHhrk plus 0.1 g of the -galactosidase reporter pCMV (Clontech, Palo Alto, CA ). Six hours after transfection, the medium was changed and the indicated treatments were added. Sixteen hours later, the monolayers were fixed for 5 minutes in a solution containing 5.4% wt / vol formaldehyde and 0.8% wt /vol glutaraldehyde in phosphate -buffered saline ( PBS ). Then, the fixative was removed; the cells were covered by staining solution and incubated at 378C until the blue precipitate appeared. The staining solution contained 1 mg /mL X -Gal (5 -bromo -4 -chloro-3-indolyl --D -galactoside ) (Gibco BRL ), 2 mM MgCl 2 , 5 mM K 3 Fe( CN ) 6 , and 5 mM K 4 Fe( CN ) 6 in PBS. Finally, the monolayers were photographed using a digital camera ( Pixera, Los Gatos, CA ), or the morphology of the blue cells was examined and the proportion of apoptotic cells was calculated. As a negative control, cells were transfected with the plasmid pGL2 -Basic instead of pBEHhrk. As a positive control for induction of apoptosis, we used a plasmid with constitutive expression of harakiri ( pcDNA3 -hrk ). 32 
Construction and verification of AdEHhrk
The AdEHhrk virus is an E1 -deleted, replication -defective adenovirus vector for the expression of harakiri under the control of the ERE /HRE promoter. It was constructed using a Cre ±Lox system. 34 Briefly, the BglI±SalI fragment from pBEHhrk, containing the therapeutic cassette, was subcloned into the shuttle plasmid pACpL + LoxP using the bluntended KpnI site. The cassette was flanked by insulator sequences ( bovine growth hormone transcription stop signals ) present in the plasmid pcDNA3 (bp 1000 ± 1250 ). 35 This fragment was obtained either by digestion of pcDNA3 (Invitrogen, Carlsbad, CA ) with PvuII and NotI, or by polymerase chain reaction (PCR ) amplification using the primers 5
H TTAGAATTCATAGTGTCACCTAAATGCTAG 3 H and 5 H AGCCGGTACCATCCCCAGCATGCCTGCTAT-TG 3
H . One copy of each of these insulators was subcloned into BamHI and EcoRI sites of pACpL +loxP, respectively. The final shuttle plasmid ( pACEHhrk ) was linearized by digestion with PmlI and used in the Cre -recombinase reaction to reconstitute a functional adenovirus genome ( University of Michigan vector core ).
Once the virus had been produced, viral DNA was isolated and PCR was used to confirm the structure of the viral genome. Two combinations of primers were used. The first one amplified the last 250 bp of the harakiri gene. The primers are 5 H TTGTAGGAACGCGGGGCTTCTTGG 3
H . In the second PCR reaction, the latter primer was used together with a primer complementary to a portion of the packaging signal of adenovirus, 5 H TAGTGTGGCGGAAG-TGTGATGTTG 3
H . To confirm that the harakiri gene was expressed in cells infected by AdEHhrk, we performed reverse transcription (RT ) PCR reaction from T-47D cells infected in the presence of estrogens. Total RNA was extracted using Trizol reagent (Gibco BRL ), and cDNA was produced using SuperScript II RT (Gibco BRL ) with an oligo-dT primer (T 30 VN ). The cDNA was amplified using the primers specific for the harakiri sequence described above.
Analysis of the viability of cells
Cells (typically 25Â10
3 /well ) were plated in 24 -well cell culture clusters ( Costar, Cambridge, MA ). When indicated, cells were pretreated with estrogens, tamoxifen, or hypoxia for 7 hours before infection. Infection was done for 1 hour in 200 L culture medium, and then 300 L of medium with treatments was added. To quantify the viability of cells after infection, the MTT assay was used (Sigma ). At the time of analysis, cells were washed with PBS, and 250 L of medium containing 50 L of 5 mg / mL Thiazolyl blue ( MTT ) solution was added. Five hours later, 250 L of solubilization solution (20% wt /vol SDS in 50% vol /vol N,N -dimethylformamide ) was added, and 12 hours later, the absorbance at 600 nm was measured in spectrophotometer. The significance of the differences observed was analyzed using the Student's t test.
RESULTS
Construction and characterization of a promoter containing EREs and HREs
To obtain a promoter that would be preferentially active in ER + cells growing under hypoxic conditions, we inserted a cassette containing three HREs in the previously described pBERE plasmid. 15 This is a luciferase reporter plasmid that contains a promoter composed of a portion of the pS2 promoter ( À 90/ + 10 bp ), with two EREs that confer its estrogen responsiveness. 33 The new construct was named pBERE /HRE. The sequences of each ERE and HRE are GGTCACAGTGACC and TGTCACGTCCTGCAC-GAC, respectively. To demonstrate that the hybrid promoter can be activated by estrogens specifically in ER + cells, and that it can respond to hypoxia, pBERE /HRE was transfected in four different human breast cancer cell lines, and luciferase assays were performed as described in Materials and Methods. MCF7, T-47D, and BT-474 are ER + cell lines, and MDA -MB-231 is ER À . In Figure 1 , the graphics A ±D represent the specific luciferase activity obtained for each cell type, respectively. The basal activity ( labeled as B in the horizontal axis ) corresponds to the transfection of the promoterless luciferase reporter pGL2 -Basic. The cells were deprived of estrogens for 24 hours before the transfection. Seven hours after transfection, some cells were maintained in estrogen -free medium ( C ), some were treated with 2.5 nM 17 -Estradiol ( E ), and others were treated with 2.5 nM 17 -Estradiol plus 2.5 M 4-OH -Tamoxifen (E + T ). When indicated, the cells were maintained under hypoxic conditions ( 1% oxygen ) during the treatment period ( H ). Finally, some cells were treated with estrogens plus hypoxia ( E +H ). As expected, the luciferase activity was stimulated by estradiol in all the ER + cells (from 30 -fold in T-47D cells to 100-fold in BT-474 cells), whereas the ER À cell line MDA -MB -231 was not activated. The activation was mediated by ERs because the competitive inhibitor tamoxifen blocked the estradiol activation more than 80% in all the cases. Interestingly, hypoxia consistently activated the ERE / HRE promoter both in ER + and ER À cells, although the stimulation was lower than in the case of estrogens ( 3.5-to 35 -fold ). Similar results were obtained when the hypoxia pathways were chemically induced by treatment with cobalt chloride ( data not shown). Finally, the combination of estradiol and hypoxia, which is supposed to mimic the in vivo scenario of breast tumors, achieved a maximum effect in ER + cells (from 40 -fold in T-47D to more than 200 -fold in BT-474 cells). These data demonstrate that hypoxia and EREs can be combined in a single promoter and they retain their ability to respond to each particular stimulus. To demonstrate the specificity of the activation, a luciferase reporter containing a constitutive promoter ( pGL2 -Control ) was transfected in MCF7 cells and subjected to the same treatments. Neither estradiol nor hypoxia caused a significant activation of this promoter.
Regulated induction of apoptosis by expression of Hrk under the control of the ERE / HRE promoter
Once we had assessed the responsiveness of the ERE / HRE promoter with the luciferase reporters, we investigated if it could have therapeutic value for gene therapy of cancer. We constructed a plasmid ( pBEHhrk ) that expresses the pro -apoptotic gene harakiri under the control of the new hybrid promoter. Hrk, the product of the harakiri gene, is a potent inductor of apoptosis that was originally characterized using HEK 293T cells. 32 We performed transient transfections of pBEHhrk in MCF7 cells, together with a lower amount of a -galactosidase reporter plasmid ( pCMV ) to identify the transfected cells after X -Gal staining. The cells had been deprived of estrogens before and during the transfection. Then, some cells were left untreated, and others were treated for 20 hours with different combinations of 17 -Estradiol, tamoxifen, or hypoxia as indicated in Figure 2 . Among the X -Gal ±positive cells, those that suffered apoptosis were recognized by morphological parameters (Fig 2A ) , and the proportion of apoptotic versus live cells is represented in the graphic of Figure 2B . In good correlation with the transcriptional activation analyzed in Figure 1A , MCF7 cells transfected with pBEHhrk quickly became apoptotic in the presence of estrogens, and this effect could be partially blocked by the antiestrogen tamoxifen. Although less efficiently than estradiol ( 50% vs. 80%; Fig 2B ) , hypoxia could also activate the apoptotic effect of pBEHhrk. Both estradiol and estradiol HERNANDEZ -ALCOCEBA, PIHALJA, NUNEZ, ET AL: TRANSCRIPTIONAL TARGETING OF BREAST CANCER plus hypoxia achieved full activation in this experimental system because they mimicked the effects of pcDNA3hrk, a plasmid with constitutive expression of Hrk (Fig 2A,  panel 6 ). As a negative control, the cells were transfected with the plasmid pGL2 -Basic, and no induction of apoptosis was observed under any of the treatment conditions (Fig 2B ) .
Construction of an E1 -deleted adenovirus for the regulated expression of Hrk
Previous attempts to construct an adenovirus for the expression of the harakiri gene using a constitutive promoter were unsuccessful, probably because the potent and rapid induction of apoptosis prevented the amplification of the viral particles. The ERE /HRE promoter offers the opportunity to modulate the expression of this lethal gene and, therefore, it might be compatible with the production of an adenoviral vector. To test this possibility, the cassette containing the harakiri gene under the control of the ERE /HRE promoter was subcloned in the plasmid pACpL + LoxP. This is a shuttle plasmid for the production of adenoviral vectors using an in vitro Cre± Lox system. 34 The cassette was flanked by insulator sequences (bovine growth hormone transcription stop signal) to avoid the interference of surrounding viral enhancers and promoters. 35 The final shuttle plasmid was named pACEHhrk. A schematic representation of the viral genome is shown in Figure 3A . After viral plaques were obtained, the structure of the vector was analyzed by PCR. Figure 3B shows the products of PCR reactions using combinations of the primers 1, 2, and 3 as indicted in Figure 3A . DNA extracted from the new vector ( AdEHhrk ) was used as a template. Using the primers 1 and 2, a 250 -bp fragment corresponding to the 3 H end of the harakiri gene is amplified. When the primers 3 and 2 are used, a 1600 -bp fragment that comprises the packaging signal of adenovirus, one of the insulators, the poly A, and the last 250 bp of the harakiri gene (is obtained). As a positive control, the pACEHhrk shuttle plasmid was used as a template. DNA extracted from the empty E1 -deleted adenoviral vector Ad5ÁE1 was used as a negative control.
Then, we tested the ability of the new vector to express the harakiri gene. T-47D cells were infected with AdEHhrk or the control virus Ad5ÁE1 at a multiplicity of infection ( MOI ) of 1000 virus /cell in the presence of 17 -Estradiol. Five hours after infection, total RNA was extracted from the cells and a RT-PCR reaction was performed using oligo -dT primers as described in Materials and Methods. The cDNA was used as a template for a PCR reaction using the primers 1 and 2 indicated in Figure 3A . As shown in Figure 3C , only the cDNA extracted from AdEHhrk -infected cells yielded a PCR product of the right size. No amplification was observed in the case of Ad5ÁE1 or if the RNA from AdEHhrk -infected cells was used without RT-PCR reaction. In the ERE / HRE promoter, the gray thick arrow represents the portion of the pS2 promoter. The two copies of the ERE are represented as a box with horizontal strips, and the three copies of the HRE are represented as a box with vertical strips. The consensus sequences for these elements are indicated above. ITR: inverted terminal repeat. The positions of the primers used for the PCR are indicated as small arrows. B: PCR reaction using as a template the pACEHhrk shuttle plasmid, or DNA extracted form AdEHhrk and Ad5ÁE1. The primers used are indicated in numbers according to the scheme in ( A ). C:
RT -PCR to demonstrate expression of the harakiri gene. T -47D cells were infected with AdEHhrk or the control virus Ad5ÁE1 ( MOI = 1000 virus / cell ) in the presence of 17 -Estradiol. Five hours after infection, total RNA was extracted from the cells and cDNA was produced in a RT reaction using oligodT primers. The cDNA was used as a template for a PCR reaction using the primers 1 and 2. The negative controls include absence of template in the PCR reaction ( control ), or using as a template the RNA of AdEHhrk -infected cells before the RT reaction ( lane labeled as RNA ). In the control line, no template was added to the PCR reaction.
AdEHhrk induces cell death in response to estrogens and hypoxia
Once the AdEHhrk virus had been produced and characterized, we tested if it could induce cell death in a controlled fashion. The transfection assays using the pBEHhrk plasmid strongly suggested that the ERE /HRE promoter could control the expression of Hrk to kill the cells in response to estrogens and hypoxia. However, it is known that in some cases, the exogenous genes inserted in adenoviral genomes lose their original transcriptional regulation due to enhancers and promoters present in the virus. 36 To investigate this possibility, T-47D cells were infected with AdEHhrk at a MOI of 2000 virus /cell. Cells were pre -treated for 7 hours before the initiation of infection, and after that, treatment was maintained until the end of the experiment, typically 20 hours postinfection. At that time, the cells were either photographed, or a viability assay (MTT ) was performed. 37 Figure 4A shows microphotographs of representative fields in the monolayers, and the graphic in Figure 4B represents the percentage of infected cells that survived, compared to the uninfected cells exposed to the same treatment. The infection with AdEHhrk in the absence of estrogens caused less than a 25% decrease in the viability of cells. In contrast, when estradiol was added, approximately 75% of cells had died in less than 24 hours according to the MTT assay. The panel 3 of Figure 4A shows the rounding and detachment of most of the cells in the monolayer. As expected, the addition of tamoxifen blocked the effect of estrogens, increasing the viability of the cells to nearly the same ( 90% ) as the uninfected control. When the infected cells were exposed to hypoxic conditions, the viability was reduced to less than 50%, and again a combination of estrogens and hypoxia achieved the maximum effect with a 90% death rate. To demonstrate the specificity of the response, the same treatments were added to cells infected with other E1 -deleted adenoviral vectors. Ad5ÁE1 does not express any exogenous gene, and Ad5LacZ expresses the LacZ gene. When used at the same MOI of 2000 virus / cell, no significant reduction of viability of the cells was observed after 20 hours of infection (Fig 4B ) , in contrast with the dramatic effects described for AdEHhrk.
AdEHhrk preferentially kills ER + cells or cells growing under hypoxic conditions
The goal of the present strategy is to selectively deliver a lethal gene into breast cancer cells, combining characteristics of the cells (expression of ERs ) and microenvironment conditions of tissues ( hypoxia associated with solid tumors ). To study if AdEHhrk preferentially kills ER + cells, or cells growing under hypoxic conditions, we infected four additional human cancer cell lines. Two of them are ER + (MCF7 and BT-474) and the other two are ER À (MDA -MB -231 and SK -BR -3 ). Among different cell lines, there are many parameters that can affect the sensitivity to the lethal effect of AdEHhrk. First, they have different susceptibility to the infection of adenovirus. Using Ad5LacZ, we found that SK -BR -3 had the highest rate of infection, followed by BT-474, MDA -MB -231, T-47D, and finally MCF7 ( data not shown ). Second, the ability of Hrk to induce apoptosis may depend on the expression of other components of the pathways controlling programmed cell death, and these can vary from one cell line to the other. 38 Keeping in mind these considerations, we performed the infection of cells at a MOI of 6000 virus / cell in the absence or presence of estradiol and hypoxia. The viability of cells after 20 hours of infection is shown in Figure 5 . In the presence of estradiol, the ER + cells were significantly more sensitive to AdEHhrk than the ER À cells (30% viability vs. 85% on average, P < .001). When estrogens were omitted in the culture medium, the cytotoxic effect of AdEHhrk was attenuated in the ER + cells (30% vs. 65% survival rate on average, P< .01 ), whereas the viability of the ER À cells was basically unchanged (P > .5). The absence of estrogens is not the usual scenario in vivo, so this suggests that AdEHhrk is only active under physiological conditions if the cells express ERs. In this circumstance, we tested the effect of the virus on the viability of normal primary fibroblasts extracted from human breast (NB2F cells ) because this is one of the nontumorigenic cell types that would be more exposed to the virus. The data show that NB2F cells were especially resistant to the lethal effect of AdEHhrk ( 90% viability ). Finally, to mimic the conditions inside a tumor, we treated the cells with estrogens and hypoxia. As expected, both ER + and ER À cell lines showed a significant decrease in viability compared to normoxic conditions ( P <.01 ), which means that hypoxia can activate the function of AdEHhrk regardless of the ER status of the cell. The viability of NB2F cells remained high even under hypoxic conditions, but it can be due in part to a low sensitivity to viral infection. Taken together, these results suggest that, at least in this experimental model, the expression of ERs and the existence of an hypoxic environment are the most important factors determining the sensitivity of different human breast cancer cells to the lethal effect of AdEHhrk.
DISCUSSION
The gene therapy strategies based on the selective expression of lethal genes have great promise for the treatment of cancer. 29 ± 31 Once a promoter that is preferentially activated in a particular kind of cancer is identified, this approach can be readily applied. The system can benefit from new HERNANDEZ -ALCOCEBA, PIHALJA, NUNEZ, ET AL: TRANSCRIPTIONAL TARGETING OF BREAST CANCER improvements in gene transfer technologies such as replication-competent adenoviruses and other new vectors. 39, 40 In addition, the search of new tumor-specific promoters can be optimized by screening techniques such as differential display and serial analysis of gene expression. 41, 42 However, there is not guarantee that a specific promoter would be found for all kinds of cancers in the near future. To overcome this limitation, the use of artificial hybrid promoters offers an alternative. These kinds of dual promoters have been described using HREs and cytokineinducible enhancers, 25 or tissue -specific and cell cycle ± regulated elements. 43 In this work, we add new evidence supporting that individual response elements can be combined in the same promoter to complement and enhance its properties. Furthermore, we have tested the performance of the promoter using an adenoviral vector. In the ERE / HRE harakiri cassette described here, the EREs direct the expression of the pro -apoptotic gene to ER + cells in the presence of estrogens, and the HREs activate the system under hypoxic conditions. Both stimuli can work independently, and they do not interfere with each other.
We observed that hypoxia did not always increase the killing rate of AdEHhrk above the effect shown in cells treated with estrogens ( Fig 5) . This suggests that once a threshold level of Hrk expression is achieved for a particular cell line, that is enough to get a full apoptotic response. Keeping in mind this possibility, the low basal activity was the most important parameter considered in the design of the ERE /HRE promoter.
This approach has great flexibility because two or more elements can be arranged in different combinations. Many tumors retain the expression of proteins that characterize the tissue of origin. In the case of breast cancer, the use of EREs can be useful to limit the action of a local injection of the virus, and it offers the possibility of regulation with antiestrogenic drugs such as tamoxifen. If the elimination of the normal tissue is supposed to cause great toxicity, the system could be engineered in a way that both the tissuespecific and the hypoxia-specific elements will be necessary to activate cell death. This could be done by controlling separately the expression of the DNA -binding domain and the transactivation domain of a transcription factor that, once fused together, can activate the expression of the lethal gene.
In our model, the modulation with estrogens was used to test the responsiveness of the promoter, but this probably has little relevance in vivo. In contrast, the inhibition with tamoxifen, and especially the attenuation of the effect in ER À cells, are the key issues in this approach. The product of gene harakiri is a potent inductor of apoptosis. It is a member of the BH3 -only subfamily of pro -apoptotic Bcl -2 proteins that act, at least in part, by binding to and inactivating the antiapoptotic proteins Bcl -2 and Bcl -x L . 32 We have observed quick and massive cell death in permissive cells transfected with the pBEHhrk plasmid or infected with AdEHhrk when the expression of the gene was activated by estrogens and /or hypoxia. The construction of a conventional E1 -deleted adenovirus was useful to demonstrate that the system retains its properties in the context of this kind of vectors. However, the pro-apoptotic replicationdeficient adenoviruses themselves may have delivery problems that limit their use for the treatment of solid tumors in vivo. To solve this problem, replication-competent adenoviruses can be used in combination with E1 -deleted adenoviral vectors like AdEHhrk to complement their E1A deletion in trans. 44 This method allows controlled replication of both viruses because when they co-infect a population of cells, the conditionally replicative adenovirus provides the E1A protein only in the permissive cells. We have recently described that this kind of cooperation amplifies the killing effect of Ad5Bcl -xs, an E1A -deleted adenoviral vector that expresses the pro -apoptotic gene Bcl -xs. 29 This vector was used in combination with Ad5ERE2, an adenovirus that preferentially replicates in ER + cells, because both E1A and E4 transcription units are controlled by a promoter that contains EREs. 15 In addition, we are currently investigating the use of dual -specificity promoters similar to the one described here to direct the expression of E1A and E4 genes in the context of a conditionally replicative adenovirus. We propose the development of similar strategies to obtain new artificial promoters and viruses specifically designed to target each particular type of cancer.
